Patients with ESCC who were not selected for PD-L1 expression appeared to benefit from PD-1 inhibitors in three clinical trials in phase 3, with objective response rates (ORRs) ranging from 16.7 to 20.2%6–8. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.